左乳浸润性导管癌合并射血分数降低的心力衰竭女性全乳切除术后辅助放疗可能与更优生存相关
本研究纳入646例临床I-IIIC期左乳浸润性导管癌合并射血分数降低的心力衰竭、接受根治性全乳切除术后辅助或未辅助放疗的女性,采用倾向评分逆概率治疗加权构建伪研究队列并行多因素分析。加权模型中辅助放疗与全因死亡风险降低独立相关(aHR 0.52,95%CI 0.37-0.74,P=0.0003),局部区域复发aHR 0.90(95%CI 0.79-0.96,P=0.0356),远处转移aHR 0.89(95%CI 0.54-1.50,P=0.6854)。作者结论为辅助放疗与全因死亡及局部区域复发减少相关。
要点
- 加权模型中辅助放疗与全因死亡风险降低独立相关(aHR 0.52,95%CI 0.37-0.74,P=0.0003)。
- 辅助放疗组局部区域复发aHR 0.90(95%CI 0.79-0.96,P=0.0356)。
- 辅助放疗组远处转移aHR 0.89(95%CI 0.54-1.50,P=0.6854),未达统计学显著。
核心结论
- 与未辅助放疗相比,辅助全乳切除术后放疗与左乳浸润性导管癌合并射血分数降低的心力衰竭女性全因死亡减少及局部区域复发减少相关。
研究设计与样本
- 纳入646例临床I-IIIC期左乳浸润性导管癌合并射血分数降低的心力衰竭、接受根治性全乳切除术的女性,按是否接受辅助全乳切除术后放疗分为两组。
- 计算倾向评分并应用逆概率治疗加权创建伪研究队列,对倾向评分加权人群行多因素分析获得风险比(HR)。
主要发现
- 在逆概率治疗加权调整模型中,辅助全乳切除术后放疗是全因死亡的显著独立预后因素(aHR 0.52,95%CI 0.37-0.74,P=0.0003)。
- 与未辅助放疗组相比,辅助放疗组局部区域复发的aHR为0.90(95%CI 0.79-0.96,P=0.0356)。
- 与未辅助放疗组相比,辅助放疗组远处转移的aHR为0.89(95%CI 0.54-1.50,P=0.6854)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, no data on the effect of adjuvant postmastectomy radiotherapy (PMRT) on oncologic outcomes, such as all-cause death, locoregional recurrence (LRR), and distant metastasis (DM), are available in women with left-side breast invasive ductal carcinoma (IDC) and heart failure with reduced ejection fraction (HFrEF). PATIENTS AND METHODS: We enrolled 646 women with left-breast IDC at clinical stages I-IIIC and HFrEF receiving radical total mastectomy (TM) followed by adjuvant PMRT or non-adjuvant PMRT. We categorized them into two groups based on their adjuvant PMRT status and compared their overall survival (OS), LRR, and DM outcomes. We calculated the propensity score and applied inverse probability of treatment weighting (IPTW) to create a pseudo-study cohort. Furthermore, we performed a multivariate analysis of the propensity score-weighted population to obtain hazard ratios (HRs). RESULTS: In the IPTW-adjusted model, adjuvant PMRT (adjusted HR [aHR]: 0.52; 95% confidence interval [CI]: 0.37-0.74) was a significant independent prognostic factor for all-cause death (P = 0.0003), and the aHR (95% CI) of LRR and DM for adjuvant PMRT was 0.90 (0.79-0.96; P = 0.0356) and 0.89 (0.54-1.50; P = 0.6854), respectively, compared with the nonadjuvant PMRT group. CONCLUSION: Adjuvant PMRT was associated with a decrease in all-cause death, and LRR in women with left IDC and HFrEF compared with nonadjuvant PMRT.
引用
- Zhang J, Sum SY, Hsu JG, et al. Adjuvant postmastectomy radiotherapy might be associated with better survival in women with heart failure receiving total mastectomy. Radiat Oncol. 2022. PMID: 35151355. doi:10.1186/s13014-022-02000-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。